Informed Prostate Cancer Patient Support

Salvage stereotactic body radiation therapy for locally recurrent prostate cancer following primary radiation therapy, are benefits worth toxicity risks?: A systematic review - Bray - The Prostate - Wiley Online Library onlinelibrary.wiley.com Gerard Bray MBBS Introduction Salvage stereotactic body radiation therapy (SBRT) for localized prostate cancer recurrence following radiation therapy remains controversial. We performed a systematic review to assess the efficacy and side effect profile of salvage SBRT for locally recurrent prostate cancer to define the role of salvage SBRT in clinical practice. Methods A systematic review was carried out using Pubmed (MEDLINE) and Scopus databases. Inclusion and exclusion criteria were

Researcher Highlights Need for Improved Understanding of Prostate Basal Cell Carcinoma onclive.com Jason Harris Basal cell carcinoma of the prostate is a rare variant of prostate cancer so uncommon that few physicians will ever treat the disease in their careers. Only 100 or so patients have been identified in the literature compared with more than 1 million diagnoses every year for adenocarcinoma. Basal cell carcinoma (BCC) of the prostate is a rare variant of prostate cancer so uncommon that few physicians will ever treat the disease in their careers. Only 100 or so patients have been identified in the literature compared with more than 1 million diagnoses every year for adenocarcinoma. There has been a long controversy around the name BCC, Michael C. Haffner, MD, PhD, assistant professor in the Human Biology Division and an assistant professor in the Clinical Research Division at

Price transparency of prostate cancer care in the United States: An analysis of pricing and disclosure following the centers for medicare and medicaid mandate | Prostate Cancer and Prostatic Diseases nature.com Shoag, Jonathan E. 9–11 minutes Abstract Background Starting January 1, 2021, Centers for Medicare and Medicaid Services required United States hospitals to publicly disclose prices of their services provided. We analyzed publicly-disclosed prices of prostate cancer-related services. Methods All United States hospitals were queried for publicly-disclosed prices of total and free prostate-specific antigen, prostate magnetic resonance imaging, prostate biopsy, radical prostatectomy, and intensity-modulated radiation therapy as of May 2022. Prices were adjusted by regional price parity. Hospitals disclosing prices were compared with non-disclosing hospitals. Results Of

Neurosurgeon Henry Marsh reflects on life and death as a cancer patient : Shots - Health News : NPR npr.org After cancer diagnosis, a neurosurgeon sees life, death and his career in a new way Terry Gross 10–12 minutes "I was much less self-assured now that I was a patient myself," says neurosurgeon Henry Marsh. "I suddenly felt much less certain about how I'd been [as a doctor], how I'd handled patients, how I'd spoken to them." Renowned British physician Henry Marsh was one of the first neurosurgeons in England to perform certain brain surgeries using only local anesthesia. For over 30 years, he also made frequent trips to Ukraine, where he performed surgery and worked to reform and update the medical system. As a surgeon, Marsh f

AI May Accurately Identify Patients for Prostate Cancer Clinical Trials, According to Expert

4 Common Causes Of CANCER That Most People Don’t Know About - YouTube

French Biotech Targeting Prostate Cancer Opens Up Trial Site in San Antonio for Phase 1b/2 Study

Active Surveillance AS101 - Part 2 - YouTube

Active Surveillance AS101 Part1 - YouTube

Untreated Prostate Cancer: Options and Progression verywellhealth.com Get Info on the Typical Progression of Prostate Cancer When Untreated Matthew Schmitz, MD 5–6 minutes Untreated prostate cancer can spread to other parts of the body. If you choose not to treat prostate cancer, which is your right, your healthcare provider will still monitor your disease and may offer treatments to help ease symptoms.  This article goes over the decision not to treat prostate cancer and what to expect if you choose to go this route. The Decision Not to Treat Prostate Cancer Decisions about prostate cancer treatment are based on your needs and preferences. There is no "right choice" for every person. Many factor in the opinions of both their healthcare team members and loved ones. But ultimately, the choice is yours. Once your provider has taken a biopsy and looked at the sample

WNT pathway mutations in metachronous oligometastatic castration-sensitive prostate cancer - ScienceDirect sciencedirect.com WNT pathway mutations in metachronous oligometastatic castration-sensitive prostate cancer ~3 minutes Access through  your institution Patient Access Outline Abstract Introduction Methods Results Discussion Conclusion References Appendix. Supplementary materials Figures (3) Tables (3) Table 3 Abstract Background WNT signaling is a cellular pathway that has been implicated in the development and progression of prostate cancer. Oligometastatic castration-sensitive prostate cancer (omCSPC) represents a unique state of disease in which metastasis-directed therapy (MDT) has demonstrated improvement in progression-free survival. Herein, we investigate the clinical implications of genomic alterations in the WNT signaling cascade in men with omCSPC. Methods We performed an

New Cancer Data Spark Outcry From Patient Advocates medscape.com New Cancer Data Spark Outcry From Patient Advocates Howard Wolinsky ~3 minutes Newly released figures showing a rise in the number of men with advanced prostate cancer have laid bare long-simmering resentment among patient advocates who feel the nation's leading cancer group has largely ignored their concerns for years. The American Cancer Society this month revealed what it called "alarming" news about prostate cancer: After two decades of decline, the number of men diagnosed with the disease in the United States rose by 15% from 2014 to 2019. "Most concerning," according to the group's CEO Karen Knudsen, PhD, MBA, is that the increase is being driven by diagnoses of advanced disease. Dr Karen Knudsen "Since 2011, the diagnosis of advanced-stage (regional- or

Multi-omics data integration approach identifies potential biomarkers for Prostate cancer | bioRxiv biorxiv.org Zedias Chikwambi bioRxiv posts many COVID19-related papers. A reminder: they have not been formally peer-reviewed and should not guide health-related behavior or be reported in the press as conclusive. 0 0 0 0 5 0 TRiP Peer Reviews 0 Community Reviews 0 Automated Evaluations 0 Blog/Media Links 0 Videos 5 Tweets Abstract Background: Prostate cancer (PCa) is one of the most common malignancies, and many studies have shown that PCa has a poor prognosis, which varies across different ethnicities. This variability is caused by genetic diversity. High-throughput omics technologies have identified and shed some light on the mechanisms of its progression and finding new biomarkers. Still, a systems biology approach is needed for a holistic molecular perspective. In this study, we applied a multi-o

Emerging systemic treatment for metastatic castration-resist... : Current Opinion in Urology journals.lww.com Emerging systemic treatment for metastatic... : Current Opinion in Urology Author Information ~4 minutes REVIEW Emerging systemic treatment for metastatic castration-resistant prostate cancer: a review of recent randomized controlled trials Yanagisawa, Takafumi a,b ; Kawada, Tatsushi a,c ; Rajwa, Pawel a,d ; Kimura, Takahiro b ; Shariat, Shahrokh F. a,e,f,g,h,i a Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria b Department of Urology, The Jikei University School of Medicine, Tokyo c Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan d Department of Urology, Medical University of Silesia, Zabrze, Poland e Division of Urolog

Risk stratification for early biochemical recurrence of prostate cancer in the era of multiparametric magnetic resonance imagining‐targeted biopsy - Diamand - The Prostate - Wiley Online Library

Treatment decision-making among patients with metastatic prostate cancer: Impact of decision locus of control on functional outcomes and decision satisfaction | Prostate Cancer and Prostatic Diseases

Prostate Cancer: Symptoms, Causes & Treatment my.clevelandclinic.org Overview 10 Warning Signs of Prostate Cancer What is prostate cancer? Prostate cancer develops in the prostate , a small walnut-shaped gland located below the bladder and in front of the rectum in men and people assigned male at birth ( AMAB ). This tiny gland secretes fluid that mixes with semen, keeping sperm healthy for conception and pregnancy. Prostate cancer is a serious disease. Fortunately, most people with prostate cancer get diagnosed before it spreads beyond their prostate gland. Treatment at this stage often eliminates the cancer. What are the types of prostate cancer? If you’re diagnosed with prostate cancer, it’s most likely an adenocarcinoma . Adenocarcinomas start in the cells of glands — like your prostate — that secrete fluid. Rarely, prostate cancer forms from other types of cells. Less common types of prostate cancers in